Reducing Sample Volume and Increasing Sensitivity for the Quantification of Human Insulin and 5 Analogs in Human Plasma Using ionKey/MS
5 May 2016

This application note demonstrates the need for robust and sensitive analysis of peptide species challenges, both through chromatographic separation and mass spectrometry. Recombinant human insulin and its analogs are perhaps the best known and most widely sold biotherapeutics. Historically, such biologics have been quantified using ligand binding assays. However, specifically in the case of insulin and analogs, these affinity-based assays lack standardization, are subject to matrix effects, and in some cases lack adequate specificity. The use of ionKey/MS facilitated a reduction in sample volume and concomitant increase in sensitivity for the quantification of human insulin and 5 important analogs.